Morana Vojnic, MD
Medical Oncology · New Brunswick, NJNPI 1942662481
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by AstraZeneca at 28.3% of the total. 2025 is the largest year on record at $7,422, more than ten times the $487 reported in 2019.
Across 66 payments — averaging $240.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Telix Pharmaceuticals$4K
- E.r. Squibb & Sons, L.L.C.$2K
- Johnson & Johnson$2K
- Novocure Inc.$1K
- GT Medical Technologies, Inc$482
- plus $2K from 13 others
Across 3 payments — averaging $17,887 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$52K
- Eli Lilly$2K
What the payments were for
- Consulting fees$9,22558%
- Travel & lodging$1,0867%
- Food & beverage$5,24533%
- Education$3352%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 8 | $4,502 |
| Telix Pharmaceuticals | 17 | $4,264 |
| E.r. Squibb & Sons, L.L.C. | 1 | $2,160 |
| Johnson & Johnson(2 entities) | 6 | $1,535 |
| Novocure Inc. | 11 | $1,188 |
| GT Medical Technologies, Inc | 3 | $482 |
| Zap Surgical Systems, Inc. | 3 | $428 |
| Boehringer Ingelheim | 2 | $242 |
| Boston Scientific | 3 | $181 |
| Galvanize Therapeutics, Inc | 1 | $148 |
| AbbVie | 1 | $146 |
| Monteris Medical Corporation | 1 | $140 |
| Jazz Pharmaceuticals Inc. | 1 | $118 |
| Seagen Inc. | 1 | $100 |
| Amgen | 1 | $99 |
| Caris MPI, Inc. | 2 | $76 |
| Kyowa Kirin, Inc. | 2 | $36 |
| Servier Pharmaceuticals LLC | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$2,220
- ILLUCCIX$1,824
- TAGRISSO$1,665
- RYBREVANT$1,337
- GammaTile$482
- Optune Gio$468
- Optune$446
- ZAP-X MV IMAGER$352
- ZAP-X TREATMENT PLANNING SOFTWARE$352
- ZAP-X TREATMENT DELIVERY SOFTWARE$352
- ZAP-X RADIOSURGERY SYSTEM$352
- ALIYA SYSTEM$148
- Venclexta$146
- Neuroblate$140
- JARDIANCE$125
- CONFIDENCE SPINAL CEMENT SYSTEM$122
- ZEPZELCA$118
How this compares
$15,890 in reported general payments places this provider in the 75th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 71 | $1,244,427 |
| Entecavir | 18 | $4,089 |
| Dexamethasone | 63 | $1,070 |
| Ondansetron OdtOndansetron | 39 | $706 |
| Levetiracetam | 15 | $122 |
| Famotidine | 14 | $86 |
| Prednisone | 15 | $14 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $4,502 | $1,244,42771 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in New Brunswick
- Kristen SpencerNew Brunswick$50K
- Sarah WeissNew Brunswick$30K
- Missak HaigentzNew Brunswick$30K
- Patrick BolandNew Brunswick$29K
- Shridar GanesanNew Brunswick$27K
- Roman GroisbergNew Brunswick$22K
- Deborah ToppmeyerNew Brunswick$21K
- Sanjay GoelNew Brunswick$13K
- Tina MayerNew Brunswick$10K
- Joseph AisnerNew Brunswick$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.